Samil Pharmaceutical Co.,Ltd (000520.KS) Stock
Samil Pharmaceutical Co.,Ltd

Company profile
Samil Pharmaceutical reported revenue of 210.25 billion KRW for fiscal year 2025, down 4.3% from fiscal year 2024. In Q1 2026 (the quarter ended March 31, 2026) revenue was 52.55 billion KRW, up 0.5% from a year before. South Korea was its largest region in fiscal year 2025, with 100% of revenue. In Q1 2026 it reported a net loss of 10.83 billion KRW, against a net loss of 9.08 billion KRW a year earlier. Our analysis of its filings shows revenue growing from 196.35 billion KRW in fiscal year 2023 to 210.25 billion KRW in fiscal year 2025, 3.5% a year on average.
What stands out
- It reported a net loss in each of its last 2 fiscal years, after a profit of 1.66 billion KRW in fiscal year 2023; the loss widened from 5.63 billion KRW in fiscal year 2024 to 34.66 billion KRW in fiscal year 2025.
- Its net profit margin over the last four reported quarters was -18.1%, against a median of 3.2% for 6 listed companies of similar size in its industry.
Figures from company filings; latest fiscal year ended December 31, 2025.
About Samil Pharmaceutical Co.,Ltd
Samil Pharmaceutical Co.,Ltd engages in the manufacture and sale of pharmaceuticals in South Korea. It offers general medicines, including Tiersil Once, EYE2O mini eye drops, and Optagent ophthalmic drops; medical devices; secret spotpatch quasi-drugs, and roll away products. The company also provides specialty medicines, such as Hycell solutions; Curelen, Ocufridine, Ocumetholone, Ocucyclo, Ocuhomapine, Ocucarpine, Allerfen, Optanac, Forus, Eymox, Cifex, and Ocuracin ophthalmic drops; and Herpecid, Forus, and Ocurasin ophthalmic ointments. Samil Pharmaceutical Co.,Ltd was founded in 1947 and is headquartered in Seoul, South Korea.
Largest shareholders
- Seung-Bum Heo9.195 %9.20%
- Kang Huh5.64 %5.64%
- Foundation Seosong2.779 %2.78%
- Gi-Jeong Lee2.305 %2.31%
- Hye-yeon Lee2.199 %2.20%
Share of the company, as of September 25, 2026
Leadership
- Seung Bum Huh — CEO & Chairman, 44
- Yu Seok Shin — President & Director, 52
- Joon Beom Huh — Executive Director, 40
How much revenue does Samil Pharmaceutical make?
Samil Pharmaceutical reported 210.25 billion KRW in revenue for fiscal year 2025, down 4.3% from 219.70 billion KRW in fiscal year 2024. In Q1 2026 revenue was 52.55 billion KRW.
Where does Samil Pharmaceutical make most of its revenue?
South Korea: 100% of revenue by region in fiscal year 2025, followed by Export (under 1%).
What companies are similar to Samil Pharmaceutical?
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Kangstem Biotech Co., Ltd. (217730.KQ), Green Cross WellBeing Corporation (234690.KQ), Ilsung Is Co., Ltd. (003120.KS), Hana Pharm Co., Ltd. (293480.KS).
Has Samil Pharmaceutical made a profit in recent years?
Net income by fiscal year: FY2021, a loss of 5.35 billion KRW; FY2022, a loss of 28.29 million KRW; FY2023, 1.66 billion KRW; FY2024, a loss of 5.63 billion KRW; FY2025, a loss of 34.66 billion KRW. It reported a net loss in 4 of these 5 years.
How does Samil Pharmaceutical's profit margin compare with similar companies?
Net profit margin over the last four reported quarters: Samil Pharmaceutical, -18.1%; Kangstem Biotech Co., Ltd. (217730.KQ), 0.0%; Green Cross WellBeing Corporation (234690.KQ), 2.9%; Ilsung Is Co., Ltd. (003120.KS), 8.5%; Hana Pharm Co., Ltd. (293480.KS), 17.4%; Yungjin Pharm. Co., Ltd. (003520.KS), -3.3%; Dongwha Pharm.Co.,Ltd (000020.KS), 3.5%.
Company Information
Contact & Links
Data as of .
How to cite: DataPorium, “Samil Pharmaceutical Co.,Ltd (000520.KS)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/000520.KS